2023.

• Jun.07.2023 Corporate

  Notice concerning the Establishment of OPhrs Co., Ltd.

• Jun.06.2023 Corporate

  Implementation of Generative AI Across the Ono Pharmaceutical Group

• Jun.05.2023 R & D

  Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

• May.31.2023 R & D

  ONO Submits Supplemental Applications for Approval of BRAFTOVI® Capsule and MEKTOVI® Tablet in Japan for the Treatment of Radically Unresectable BRAF-Mutant Thyroid Cancer

• May.29.2023 R & D

  Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%

• May.10.2023 Management / Finance

  Notice regarding Dividends of Retained Earnings

• May.10.2023 Management / Finance

  Announcement on Financial Results for FY2022

• May.10.2023 Management / Finance

  Notice regarding Differences in the Non-consolidated Financial Results between the Fiscal Year Ended March 31, 2023 and the Previous Fiscal Year

• Apr.25.2023 R & D

  Regarding the Press Release Issued on February 17 related to Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) for Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

• Apr.14.2023 Corporate

  Initiatives to Strengthen Compliance Management System

• Apr.07.2023 Corporate

  Notice regarding Complete Settlement of Lawsuit on Patents relating to Anti-PD-1/PD-L1 Antibody

• Apr.07.2023 Corporate

  Announcement on Changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers

• Apr.03.2023 R & D

  Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial

• Mar.27.2023 R & D

  ONO Receives Supplemental Approval of Opdivo in Combination with Chemotherapy for Neoadjuvant Treatment of Non-Small Cell Lung Cancer in Japan

• Mar.27.2023 Sustainability

  ONO Sets New Targets of Medium- to Long-Term Environment Vision
  - Toward Realization of Medium- to Long-Term Environment Vision, ECO VISION 2050 -

• Mar.23.2023 R & D

  Opdivo® Intravenous Infusion Approved in South Korea for the First-line Treatment of Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma in Two Combination Treatments of Opdivo + Yervoy and Opdivo + Chemotherapy

• Mar.23.2023 Licensing

  Ono Enters into a Drug Discovery Collaboration Agreement with Macomics to Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer

• Mar.23.2023 Licensing

  Ono Enters into a Drug Discovery Collaboration Agreement with MOLCURE to Discover and Develop Innovative Antibody Drugs for Multiple Targets Utilizing MOLCURE’s AI-driven Platform Technology

• Mar.22.2023 R & D

  Opdivo® Intravenous Infusion Approved in Combination with Yervoy in Taiwan for the Treatment of Hepatocellular Carcinoma Previously Treated with Sorafenib

• Mar.15.2023 Licensing

  Ono Enters into a Drug Discovery Collaboration Agreement with PeptiDream to Discover and Develop Macrocyclic Constrained Peptide Therapeutics

• Mar.01.2023 R & D

  U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

• Feb.28.2023 R & D

  ONO Submits Supplemental Application for Approval of Opdivo® in Japan to Expand its Use for the Treatment of Malignant Mesothelioma (Excluding Malignant Pleural Mesothelioma)

• Feb.22.2023 Licensing

  Ono Enters into a Collaboration and Option Agreement with Cue Biopharma for CUE-401, a Bispecific Protein

• Feb.22.2023 R & D

  Opdivo® Intravenous Infusion Approved for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Combination with Chemotherapy in Taiwan

• Feb.20.2023 R & D

  Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial

• Feb.17.2023 R & D

  Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

• Feb.15.2023 Corporate

  Support for Relief Efforts in the Earthquake in Turkey and Syria

• Feb.08.2023 Sustainability

  Release of Video titled “Surviving Cancer” that Conveys the Thoughts of Cancer Patients

• Jan.31.2023 Management / Finance

  Announcement on Financial Results for FY2022 3Q

• Jan.31.2023 Corporate

  Notice Concerning the Establishment of “Ono Pharma Oncology, Immunology, Neurology Research Foundation,” a General Incorporated Foundation

• Jan.25.2023 Licensing

  Ono Acquires Multiple Research-Stage Oncology Programs from KSQ Therapeutics

• Jan.16.2023 Corporate

  Notice concerning the Start of Joint Transportation in the Domestic Distribution of Prescription Pharmaceuticals

• Jan.13.2023 Licensing

  Ono Enters an Option and Research Collaboration Agreement with Monash University to Discover Anti-GPCR Antibodies in the Autoimmune and Inflammatory Diseases

• Jan.13.2023 Corporate

  Notice concerning Certification as a “DX Certified Business Operator” Stipulated by the Ministry of Economy, Trade and Industry

• Jan.10.2023 Products

  Revision of Electronic Package Insert of Forxiga, a Selective SGLT2 inhibitor, related to Indication of Chronic Heart Failure